P21-activated kinases (PAKs) are involved in the regulation of multiple processes including cell proliferation, adhesion and migration. However, the current knowledge about their function is mainly based on results obtained in adherent cell types. We investigated the effect of group I PAK inhibition using the compound IPA-3 in a variety of human leukemic cell lines (JURL-MK1, MOLM-7, K562, CML-T1, HL-60, Karpas-299, Jurkat, HEL) as well as in primary blood cells. IPA-3 induced cell death with EC50 ranging from 5 to more than 20 μM. Similar range was found for IPA-3-mediated dephosphorylation of a known PAK downstream effector, cofilin. The cell death was associated with caspase-3 activation, PARP cleavage and apoptotic DNA fragmentation. In parallel, 20 μM IPA-3 treatment induced rapid and marked decrease of the cell adhesivity to fibronectin. Per contra, partial reduction of PAK activity using lower dose IPA-3 or siRNA resulted in a slight increase in the cell adhesivity. The changes in the cell adhesivity were also studied using real-time microimpedance measurement and by interference reflection microscopy. Significant differences in the intracellular IPA-3 level among various cell lines were observed indicating that an active mechanism is involved in IPA-3 transport.

Department of Cellular Biochemistry Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Arias-Romero LE, Chernoff J (2008) A tale of two paks. Biol. Cell. 100: 97–108. PubMed

Kichina JV, Goc A, Al-Husein B, Somanath PR, Kandel ES (2010) PAK1 as a therapeutic target. Expert Opin. Ther. Targets 14: 703–725. PubMed PMC

Coniglio SJ, Zavarella S, Symons MH (2008) Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Mol. Cell. Biol. 28: 4162–4172. PubMed PMC

Arai A, Jin A, Yan W, Mizuchi D, Yamamoto K, et al. (2005) SDF-1 synergistically enhances IL-3-induced activation of the raf-1/MEK/Erk signaling pathway through activation of rac and its effector pak kinases to promote hematopoiesis and chemotaxis. Cell. Signal. 17: 497–506. PubMed

Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R (2006) PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 25: 2931–2936. PubMed

Parekh P, Rao KV (2007) Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, akt and Pak1 during diethylnitrosamine-induced progressive liver carcinogenesis. Cell Biol. Int. 31: 35–43. PubMed

Kamai T, Shirataki H, Nakanishi K, Furuya N, Kambara T, et al. (2010) Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. BMC Cancer 10: 164–2407–10–164. PubMed PMC

McCarty SK, Saji M, Zhang X, Jarjoura D, Fusco A, et al. (2010) Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr. Relat. Cancer 17: 989–999. PubMed PMC

Lee MY, Kim SH, Ihm HJ, Chae HD, Kim CH, et al. (2011) Up-regulation of p21-activated kinase 1 by in vitro treatment with interleukin 1-beta and its increased expression in ovarian endometriotic cysts. Fertil. Steril. 96: 508–511. PubMed

Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, et al. (2011) Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc. Natl. Acad. Sci. U. S. A. 108: 7177–7182. PubMed PMC

Sato M, Matsuda Y, Wakai T, Kubota M, Osawa M, et al. (2013) P21-activated kinase-2 is a critical mediator of transforming growth factor-beta-induced hepatoma cell migration. J. Gastroenterol. Hepatol. PubMed

Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, et al. (2013) P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J. Natl. Cancer Inst. PubMed

Hoover WC, Zhang W, Xue Z, Gao H, Chernoff J, et al. (2012) Inhibition of p21 activated kinase (PAK) reduces airway responsiveness in vivo and in vitro in murine and human airways. PLoS One 7: e42601. PubMed PMC

Stockton RA, Schaefer E, Schwartz MA (2004) P21-activated kinase regulates endothelial permeability through modulation of contractility. J. Biol. Chem. 279: 46621–46630. PubMed

Walsh K, McKinney MS, Love C, Liu Q, Fan A, et al. (2013) PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin. Cancer Res. 19: 1106–1115. PubMed PMC

Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, et al. (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol. 15: 322–331. PubMed PMC

Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO (2009) PAK kinase regulates rac GTPase and is a potential target in human schwannomas. Exp. Neurol. 218: 137–144. PubMed PMC

Viaud J, Peterson JR (2009) An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol. Cancer. Ther. 8: 2559–2565. PubMed PMC

Grebenova D, Roselova P, Pluskalova M, Halada P, Rosel D, et al. (2012) Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells. J. Proteomics. PubMed

Dorrance AM, De Vita S, Radu M, Reddy PN, McGuinness MK, et al. (2013) The rac GTPase effector p21-activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment. Blood 121: 2474–2482. PubMed PMC

Tsuji-Takayama K, Kamiya T, Nakamura S, Matsuo Y, Adachi T, et al. (1994) Establishment of multiple leukemia cell lines with diverse myeloid and/or megakaryoblastoid characteristics from a single Ph1 positive chronic myelogenous leukemia blood sample. Hum. Cell 7: 167–171. PubMed

Martin P, Papayannopoulou T (1982) HEL cells: A new human erythroleukemia cell line with spontaneous and induced globin expression. Science 216: 1233–1235. PubMed

Kuzelova K, Grebenova D, Hrkal Z (2007) Labeling of apoptotic JURL-MK1 cells by fluorescent caspase-3 inhibitor FAM-DEVD-fmk occurs mainly at site(s) different from caspase-3 active site. Cytometry A. 71: 605–611. PubMed

Kuzelova K, Pluskalova M, Brodska B, Otevrelova P, Elknerova K, et al. (2010) Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. J. Cell. Biochem. 109: 184–195. PubMed

Obr A, Roselova P, Grebenova D, Kuzelova K (2013) Real-time monitoring of hematopoietic cell interaction with fibronectin fragment: The effect of histone deacetylase inhibitors. Cell. Adh Migr. 7: 275–282. PubMed PMC

Persico A, Cervigni RI, Barretta ML, Corda D, Colanzi A (2010) Golgi partitioning controls mitotic entry through aurora-A kinase. Mol. Biol. Cell 21: 3708–3721. PubMed PMC

Barr VA, Bunnell SC (2009) Interference reflection microscopy. Curr. Protoc. Cell. Biol. Chapter 4: Unit 4.23. PubMed PMC

Singhal R, Kandel ES (2012) The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and ras oncogenes. Oncotarget 3: 700–708. PubMed PMC

Bright MD, Garner AP, Ridley AJ (2009) PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell. Signal. 21: 1738–1747. PubMed

Luo S, Rubinsztein DC (2009) Huntingtin promotes cell survival by preventing Pak2 cleavage. J. Cell. Sci. 122: 875–885. PubMed PMC

Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, et al. (2010) Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: Effects on prognosis and cell invasion. Int. J. Cancer 127: 21–31. PubMed

Wu R, Abramson AL, Symons MH, Steinberg BM (2010) Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression. Int. J. Cancer 127: 2230–2237. PubMed PMC

Marlin JW, Chang YW, Ober M, Handy A, Xu W, Jakobi R (2011) Functional PAK-2 knockout and replacement with a caspase cleavage-deficient mutant in mice reveals differential requirements of full-length PAK-2 and caspase-activated PAK-2p34. Mamm. Genome 22: 306–317. PubMed

Li T, Zhang J, Zhu F, Wen W, Zykova T, et al. (2011) P21-activated protein kinase (PAK2)-mediated c-jun phosphorylation at 5 threonine sites promotes cell transformation. Carcinogenesis 32: 659–666. PubMed PMC

Lee N, MacDonald H, Reinhard C, Halenbeck R, Roulston A, et al. (1997) Activation of hPAK65 by caspase cleavage induces some of the morphological and biochemical changes of apoptosis. Proc. Natl. Acad. Sci. U. S. A. 94: 13642–13647. PubMed PMC

Rudel T, Bokoch GM (1997) Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276: 1571–1574. PubMed

Kuzelova K, Grebenova D, Brodska B (2011) Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes. J. Cell. Biochem. 112: 3334–3342. PubMed

Yang L, Wang L, Geiger H, Cancelas JA, Mo J, Zheng Y (2007) Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow. Proc. Natl. Acad. Sci. U. S. A. 104: 5091–5096. PubMed PMC

Tybulewicz VL, Henderson RB (2009) Rho family GTPases and their regulators in lymphocytes. Nat. Rev. Immunol. 9: 630–644. PubMed PMC

Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y (2010) Rho GTPases in hematopoiesis and hemopathies. Blood 115: 936–947. PubMed PMC

Wang H, Zeng X, Fan Z, Lim B (2010) RhoH plays distinct roles in T-cell migrations induced by different doses of SDF1 alpha. Cell. Signal. 22: 1022–1032. PubMed

Daub H, Gevaert K, Vandekerckhove J, Sobel A, Hall A (2001) Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J. Biol. Chem. 276: 1677–1680. PubMed

Wittmann T, Bokoch GM, Waterman-Storer CM (2004) Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J. Biol. Chem. 279: 6196–6203. PubMed

Kosoff R, Chow HY, Radu M, Chernoff J (2013) Pak2 kinase restrains mast cell FcepsilonRI receptor signaling through modulation of rho protein guanine nucleotide exchange factor (GEF) activity. J. Biol. Chem. 288: 974–983. PubMed PMC

Group I p21-activated kinases in leukemia cell adhesion to fibronectin

PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions